Analysts expect that the resubmission of Eli Lilly & Co./Incyte Corp.'s JAK1/2 inhibitor baricitinib in rheumatoid arthritis will be successful and that the drug will be received warmly in the market by specialists, despite concerns by the US FDA about thromboembolic safety.
Lilly and Incyte announced Aug. 30 that they will be resubmitting the NDA for the once-daily JAK inhibitor in moderate-to-severe rheumatoid arthritis (RA) in the US by the end of January 2018. Since February, the drug has been approved in Europe, where it is marketed as Olumiant
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?